Ovarian Cancer

An expanded access program (EAP) was just opened up for ceratain patients with ovarian cancer to receive niraparib.

A recent study examined the relationship between polycystic ovarian syndrome, long or irregular periods and ovarian cancer risk.

Finding new biomarkers should be the top priority in ovarian cancer research, Maurie Markman, M.D., says.

The FDA approved Rubraca for patients with advanced ovarian cancer who already had two or more lines of therapy.

Psilocybin, a component found in psychedelic mushrooms, reduced cancer-related anxiety and depression in a recent trial.

Faced with cancer, some launch nonprofit organizations designed to help fellow patients and their families. Here’s how they do it.

The FDA expanded Avastin's approval to include patients with platinum-sensitive ovarian cancer.

A rock band made up of gynecologic oncologists is connecting with patients and their fans through rock music.

A phase 2 study is examining Keytruda in combination with two other agents for treatment of ovarian cancer.

A recently launched clinical trial is exploring a new agent to treat patients with advanced, recurrent, platinum-resistant ovarian cancer.

With the addition of PARP inhibitors, as well as new agents on the horizon, the treatment landscape of gynecologic cancers is progressing.

There are many misconceptions about genetic testing in cancer, but the SGO crafted a new toolkit to help patients and providers navigate the field.

Stress and depression can alter ovarian cancer tumors, often leading to poorer outcomes.

Optimizing the use of neoadjuvant chemotherapy could improve outcomes for patients with ovarian cancer.

A woman won a lawsuit against Johnson & Johnson, claiming that its baby powder caused her ovarian cancer.

Many female survivors of cancer face sexual pain after treatment, and may not feel comfortable starting a conversation with their health care providers.

Lynparza imrpoved progresion-free survival (PFS) when compared to the placebo group in a phase 3 ovarian cancer trial.

CURE spoke with Scott Richard, M.D., about ovarian cancer recurrence and barriers women may face the second time around.

A new toolkit developed by the Society for Gynecologic Oncology is aimed at increasing awareness about genetic testing for gynecologic cancers.

Mache Seibel discusses the benefits of taking estrogen supplements for women who harbor the BRCA genetic mutation.

A trial testing Zytiga's effectiveness in ovarian cancer was recently halted.

A cohort of patients with ovarian cancer saw survival benefit with niraparib in a recent phase 3 study.

Knowing the risks of ovarian cancer is extremely important. Peter Dottino discusses the risks, symptoms and management of the disease.

Last night's "In Our Genes: An Evening of Storytelling" was an event that not only raised money for research in BRCA-related cancers, but also aimed to raise the spirits of individuals who have been affected by the gene mutation.

Hammonds discusses how she leaves the scary stuff behind and focuses, instead, on the good stuff after ovarian cancer.

September is national Ovarian Cancer Month. My wife died of ovarian cancer at the age of 47. Her final wish was to swim with crocodiles. This is her story.

The NOCC is connecting women who have ovarian cancer to others who are experiencing similar struggles.

The novel agent rucaparib was granted a priority review for the treatment of patients with BRCA-positive advanced ovarian cancer who have received at least two prior lines of chemotherapy.

Neoadjuvant chemotherapy is the best option for some patients with ovarian cancer, according to a recent report.

In honor of Ovarian Cancer Month, it is only appropriate for me to discuss ovarian cancer. "Ovarian cancer" are two of the scariest words in any language for a woman to hear — screening for it at this time is poor and more often than not, by the time it is detected it is too late.